生物活性

• 描述Pirarubicin is a cell cycle nonspecific anthracycline anticancer drug^[3]. It interacts with topoisomerase II to inhibit DNA replication. Pirarubicin inhibits the growth of human HeLa and C33A cervical, as well as T-24 bladder cancer cells (IC50s = 29, 52, and 36 ng/ml, respectively)^[4]. It inhibits the growth of human Huh7 and MHCC97H liver cancer cells (IC50s = 0.159 and 0.374 μM, respectively)^[5]. Pirarubicin also inhibits the growth of M5076 mouse ovarian cancer cells in vitro (IC50 = 0.366 μM) and in vivo in a mouse allograft model when administered at a dose of 2 mg/kg for four days^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT03277716	Hepatocellular Carcinoma Non-r... more >>esectable Transarterial Chemoembolization Microwave Ablation Collapse <<	Not Applicable	Recruiting	December 30, 2021	China, Beijing ... more >> Cancer Institute &Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China, 100021 Contact: Xiao Li, M.D          China, Fujian The First Affiliated Hospital of Fujian Medical University Recruiting Fuzhou, Fujian, China, 350005 Contact: Zhenyu Lin, M.D.          The tumor hospital of Fujian Province Not yet recruiting Fuzhou, Fujian, China, 350014 Contact: Hailan Lin, M.D          China, Guangdong the First Affiliated Hospital of SunYat-senUniversity Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Jiaping Li, M.D          Shenzhen People's Hospital Recruiting Shenzhen, Guangdong, China, 518020 Contact: Yanfang Zhang, M.D.          Peking University Hospital of Shenzhen Recruiting Shenzhen, Guangdong, China, 518036 Contact: Junhui Chen, M.D.          China, Shandong The Second Affiliated Hospital of Shandong University Recruiting Jinan, Shandong, China, 250000 Contact: Yuliang Li, M.D          Shandong Province Hospital Recruiting Jinan, Shandong, China, 250014 Contact: Xin Ye, M.D          the Affiliated Hospital of Medical College Qingdao University Recruiting Qingdao, Shandong, China, 26555 Contact: Zixiang Li, M.D          China, Zhejiang The First Affiliated Hospital of Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Contact: Junhui Sun, M.D. Collapse <<
  NCT00131053	Lymphoblastic Leukemia, Acute	Phase 2	Unknown	September 2011	Japan ... more >> Department of Hematology, Nagoya University Graduate School of Medicine Recruiting Nagoya, Japan, 466-8550 Contact: Fumihiko Hayakawa, MD       bun-hy@med.nagoya-u.ac.jp    Principal Investigator: Fumihiko Hayakawa, MD Collapse <<
  NCT02760953	Urinary Bladder Neoplasms	Not Applicable	Not yet recruiting	December 31, 2018	-

• 更多
• 参考文献

• [1] Liu SY, Song SX, et al. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy. 2010;56(2):101-7.

  [2] Sugiyama T, Sadzuka Y, et al. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999 Jul;90(7):775-80.

  [3] Huang H, Chen T, Zhou Y, et al. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018;15(14):1648-1657.

  [4] Tsuchiya KS, Ishii T, Ikeno S, et al. Inhibition of anchorage-independent growth of tumor cells by IT-62-B, a new anthracycline. J Antibiot (Tokyo). 1997;50(10):853-859.

  [5] Huang H, Chen T, Zhou Y, Geng L, Shen T, Zhou L, Zheng S. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018 Nov 5;15(14):1648-1657.

  [6] Sugiyama T, Sadzuka Y, Nagasawa K, Ohnishi N, Yokoyama T, Sonobe T. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999;90(7):775-780.

• 更多

• Collapse